RecruitingPhase 1Phase 2NCT06996782

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor

AstraZeneca

Enrollment

152 participants

Start Date

Nov 24, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced or Metastatic Non-small Cell Lung Cancer

Summary

The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a multi-arm platform study testing new drug combinations for people with advanced (Stage IV) non-small cell lung cancer (NSCLC) that has spread. It tests an experimental immunotherapy drug alongside standard chemotherapy options in patients whose cancer does not have specific actionable mutations. **You may be eligible if...** - You are 18 or older with confirmed Stage IV non-small cell lung cancer - Your cancer has at least one measurable tumor on imaging - You have adequate organ and bone marrow function - For a specific sub-study: your tumor has a PD-L1 score of at least 1% and you weigh at least 30 kg **You may NOT be eligible if...** - Your tumor has specific known mutations where targeted therapy exists (such as EGFR, ALK, or others) - You have uncontrolled infections, serious heart disease, brain metastases, or severe lung disease - You have had prior systemic treatment for advanced lung cancer - You have had a prior stem cell or organ transplant - You have an active autoimmune disease requiring treatment in the past 5 years Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRilvegostomig

Rilvegostomig will be administered as an intravenous (IV) infusion.

DRUGCisplatin

Cisplatin will be administered as SoC as an IV infusion.

DRUGCarboplatin

Carboplatin will be administered as SoC as an IV infusion.

DRUGPemetrexed

Pemetrexed will be administered as SoC as an IV infusion.

DRUGPaclitaxel

Paclitaxel will be administered as SoC as an IV infusion.

DRUGNab-paclitaxel

Nab-paclitaxel will be administered as SoC as an IV infusion.

DRUGRamucirumab

Ramucirumab will be administered as an IV infusion.

Locations(104)

Research Site

Phoenix, Arizona, United States

Research Site

Santa Rosa, California, United States

Research Site

Jacksonville, Florida, United States

Research Site

Baltimore, Maryland, United States

Research Site

Detroit, Michigan, United States

Research Site

Rochester, Minnesota, United States

Research Site

Cleveland, Ohio, United States

Research Site

Providence, Rhode Island, United States

Research Site

Providence, Rhode Island, United States

Research Site

Tyler, Texas, United States

Research Site

Anderlecht, Belgium

Research Site

Hasselt, Belgium

Research Site

Leuven, Belgium

Research Site

Barretos, Brazil

Research Site

Fortaleza, Brazil

Research Site

Natal, Brazil

Research Site

Pelotas, Brazil

Research Site

Porto Alegre, Brazil

Research Site

São Paulo, Brazil

Research Site

São Paulo, Brazil

Research Site

Chengdu, China

Research Site

Chongqing, China

Research Site

Deyang, China

Research Site

Fuzhou, China

Research Site

Guangzhou, China

Research Site

Jinan, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shenyang, China

Research Site

Shenzhen, China

Research Site

Wuhan, China

Research Site

Wuhan, China

Research Site

Bordeaux, France

Research Site

Dijon, France

Research Site

Limoges, France

Research Site

Marseille, France

Research Site

Nantes, France

Research Site

Nice, France

Research Site

Paris, France

Research Site

Batumi, Georgia

Research Site

Tbilisi, Georgia

Research Site

Tbilisi, Georgia

Research Site

Tbilisi, Georgia

Research Site

Tbilisi, Georgia

Research Site

Tbilisi, Georgia

Research Site

München, Germany

Research Site

Münster, Germany

Research Site

Oldenburg, Germany

Research Site

Regensburg, Germany

Research Site

Würzburg, Germany

Research Site

Milan, Italy

Research Site

Milan, Italy

Research Site

Orbassano, Italy

Research Site

Pavia, Italy

Research Site

Roma, Italy

Research Site

Bunkyō City, Japan

Research Site

Bunkyō City, Japan

Research Site

Kashiwa, Japan

Research Site

Kurume-shi, Japan

Research Site

Kyoto, Japan

Research Site

Niigata, Japan

Research Site

Shinjuku-ku, Japan

Research Site

Toyoake-shi, Japan

Research Site

Kuala Lumpur, Malaysia

Research Site

Kuala Selangor, Malaysia

Research Site

Kuching, Malaysia

Research Site

Singapore, Malaysia

Research Site

Chisinau, Moldova

Research Site

Amsterdam, Netherlands

Research Site

Groningen, Netherlands

Research Site

Leiden, Netherlands

Research Site

Lima, Peru

Research Site

Koszalin, Poland

Research Site

Lodz, Poland

Research Site

Olsztyn, Poland

Research Site

Belgrade, Serbia

Research Site

Kragujevac, Serbia

Research Site

Niš, Serbia

Research Site

Seongbuk-Gu, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Barcelona, Spain

Research Site

Barcelona, Spain

Research Site

L'Hospitalet de Llobregat, Spain

Research Site

Madrid, Spain

Research Site

Madrid, Spain

Research Site

Pamplona, Spain

Research Site

Pozuelo de Alarcón, Spain

Research Site

Valencia, Spain

Research Site

Valencia, Spain

Research Site

Taichung, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taipei, Taiwan

Research Site

Bangkok, Thailand

Research Site

Chanthaburi, Thailand

Research Site

Hat Yai, Thailand

Research Site

Khon Kaen, Thailand

Research Site

Rachathewi, Thailand

Research Site

Ankara, Turkey (Türkiye)

Research Site

Ankara, Turkey (Türkiye)

Research Site

Fatih, Turkey (Türkiye)

Research Site

Istanbul, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06996782

Related Trials

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

NCT065120511 location

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT071709951 location

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

NCT065814191 location

Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

NCT066743431 location